Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

k related to the PROCAPS agreement which we terminated in 2012 and decreased litigation costs related to a settlement in 2011.

About Galectin TherapeuticsGalectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function.  We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development.  We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.  Additional information is available at www.galectintherapeutics.com.

Forward Looking StatementsThis press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others.  They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements.  Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product c
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Nine field ... Iowa, Illinois and Indiana. Hosted by the Soil Health Partnership , the field ... lasting environmental benefits while potentially increasing farm productivity and income. , Brent Bible has ...
(Date:8/3/2015)... GERMANTOWN, Md. , Aug. 3, 2015   ... it will release first half and second quarter 2015 ... 10 th , 2015.  The Company will host a ... results and provide a general business update. ... (Domestic US) and 1-412-902-4262 (International), and asking to join ...
(Date:8/3/2015)... Kent, WA (PRWEB) , ... August 03, 2015 ... ... TLD3000 and TLD5000 diaphragm vacuum pumps to its comprehensive line of analytical laboratory ... stainless steel valves, these versatile pumps provide a chemically resistant and maintenance-free solution ...
(Date:7/31/2015)... China Cord Blood Corporation (NYSE: CO) ("CCBC" ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has filed its Annual Report on ... The filed Form 20-F includes audited financial statements for ... 20-F can be accessed by visiting the U.S. Securities ...
Breaking Biology Technology:Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Sterlitech Launches New Line of Vacuum Pumps 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... ... will take place on May 16-19, 2010 in Baltimore, MD, USA. This innovative ... their knowledge and experience in process development, crystallization, safety, scale-up, production, and emerging technologies. ... Columbia, MD ...
... Scientists at Queen,s University Belfast are developing new sensors to ... the fight against the threat of terrorist attacks. The ... or crime scene to gather a sample which is then ... of chemicals within seconds. This will allow better, faster decisions ...
... Batteries can power anything from small sensors to ... them smaller but even more powerful, problems can arise ... the devices themselves. University of Missouri researchers are developing ... more efficient. "To provide enough power, we need ...
Cached Biology Technology:17th International Process Development Conference to Feature Presentations on Safety, Process Development, Crystallization, PAT, Scale-Up and Production 2New technology detects chemical weapons in seconds 2Researchers create smaller and more efficient nuclear battery 2
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading ... for its second quarter ended June 30, 2015.  ... million, a decrease of 33% compared to $6.8 million in ... quarter of 2015 was $0.3 million, or $0.01 per diluted ... share, in the same period a year ago.  ...
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... spontaneous organised motion of a large number of individuals. It ... and groups of insects to shoals of fish, flocks of ... Lobaskin from University College Dublin, Ireland, have uncovered new collective ... EPJ B . Ultimately, this could be used to ...
... only species with a sweet tooth. Research from North Carolina ... Drosophila suzukii ) also prefers sweet, soft fruit giving ... the United States over the past four years and threatens ... U.S. fruit crops. "Because we know that D. ...
... an extinct Australian frog has been revived and reactivated by ... a "dead" cell nucleus into a fresh egg from another ... which uniquely swallowed its eggs, brooded its young ... became extinct in 1983., But the Lazarus Project team has ...
Cached Biology News:Study offers new insights on invasive fly threatening US fruit crops 2Lost frog DNA revived: Lazarus Project 2
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Biology Products: